Panacea Biotec Appoints Vinod Goel as CFO and Ankit Jain as Company Secretary

Panacea Biotec Limited , a prominent player in the pharmaceutical industry, has announced significant changes in its key management personnel following the resignation of CFO Devender Gupta. The company's Board of Directors has approved new appointments to ensure continuity in financial and corporate governance functions.

Key Management Appointments

The Board of Directors, in its meeting held on December 15, 2025, approved the following key appointments pursuant to Regulation 30 of SEBI LODR Regulations:

Position:	Name	Designation	Effective Date
Chief Financial Officer	Vinod Goel	Group CFO and Head Legal Corporate Governance	December 16, 2025
Company Secretary	Ankit Jain	General Manager-Legal Company Secretary	December 16, 2025

New CFO Profile and Background

Vinod Goel, aged about 60 years, brings extensive experience to his new role. He is a fellow member of the Institute of Company Secretaries of India and an associate member of the Institute of Cost Accountants of India. Goel holds B.Com.(Hons.), M.Com. and LL.B. degrees and has over 35 years of post-qualification experience in corporate governance, contracts negotiation, litigation management, costing, finance, internal audit, funds raising, investor relations, mergers & acquisitions, and corporate restructuring.

Goel has been associated with Panacea Biotec Limited since 1999 and has held various senior-level positions. He was previously serving as Group CFO and Head Legal Company Secretary of the company. Consequently, he will cease to be the Company Secretary and Compliance Officer with effect from December 15, 2025.

New Company Secretary Appointment

Ankit Jain, aged about 38 years, has been appointed as the new Company Secretary and Compliance Officer. He is an associate member of the Institute of Company Secretaries of India (A29499) and holds B.Com. and LL.B. degrees along with a Diploma in taxation laws and IPR. Jain brings around 15 years of experience in corporate governance, regulatory compliance, litigation management, contract management, merger & acquisition, and strategic planning.

Jain was previously working as Assistant General Manager-Legal of the company's wholly-owned subsidiary, Panacea Biotec Pharma Limited, since March 2024, where he was actively engaged in secretarial and legal functions.

Transition Context

These appointments follow the resignation of Devender Gupta from the position of Chief Financial Officer, who stepped down on December 15, 2025, citing personal reasons. The appointments were made based on the recommendation and approval of the Nomination Remuneration Committee and Audit Committee.

Revised Key Managerial Personnel Structure

The company has revised its policy for determining materiality of events and authorized the following Key Managerial Personnel for disclosure purposes under SEBI LODR Regulations, effective December 16, 2025:

Position:	Name
Chairman and Managing Director	Dr. Rajesh Jain
Joint Managing Director	Sandeep Jain
Whole-time Director	Ankesh Jain
Whole-time Director	Harshet Jain
Whole-time Director	Dr. Sanjay Trehan
Group CFO and Head Legal Corporate Governance	Vinod Goel
General Manager-Legal Company Secretary	Ankit Jain

The Board meeting commenced at 3:00 PM and concluded at 3:36 PM on December 15, 2025. These strategic appointments demonstrate the company's commitment to maintaining strong financial leadership and corporate governance standards during this management transition.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.83%	+3.23%	+3.70%	-13.73%	-17.10%	+55.38%

Panacea Biotec , a prominent player in the Indian pharmaceutical sector, has reported its financial results for the second quarter, revealing a significant increase in net loss and a decline in revenue.

Financial Performance Overview

Metric	Q2 (Current Year)	Q2 (Previous Year)	Change
Net Loss	₹139.00 million	₹48.00 million	+189.58%
Revenue	₹1.40 billion	₹1.47 billion	-4.76%
EBITDA	-₹178.00 million	₹70.00 million	-354.29%

Key Highlights

Widened Net Loss: Panacea Biotec's consolidated net loss for the quarter increased to ₹139.00 million, nearly tripling from ₹48.00 million in the same period last year.
Revenue Decline: The company experienced a year-over-year revenue decline, with Q2 revenue dropping to ₹1.40 billion from ₹1.47 billion in the previous year.
EBITDA Deterioration: The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) shifted from a positive ₹70.00 million in the prior year's quarter to a loss of ₹178.00 million.

Operational Performance

The substantial shift in EBITDA from a gain to a significant loss indicates a marked deterioration in Panacea Biotec's operational performance. This change suggests the company may be facing challenges in managing its operating costs effectively or experiencing pressure on its profit margins.

The widening net loss, coupled with declining revenue, points to a challenging quarter for Panacea Biotec. These results may prompt investors and analysts to closely monitor the company's future strategies and performance in the coming quarters.

As the pharmaceutical sector continues to evolve, Panacea Biotec's management may need to address these financial challenges and explore avenues for revenue growth and cost optimization to improve its financial health.